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Parkinson’s disease (PD) is a neurodegenerative condition characterized by chronic inﬂammation. Nuclear factor κB( N F - κB) is a
familyofinducibletranscriptionfactors thatareexpressed inawidevarietyofcells andtissues,includingmicroglia,astrocytes,and
neurons, and the classical NF-κB pathway plays a key role in the activation and regulation of inﬂammatory mediator production
duringinﬂammation.Activation ofthe classicalNF-κB pathwayismediated through theactivity oftheIKK kinasecomplex, which
consistsof a heterotrimer of IKKα,I K K β,a n dI K K γ subunits. Targeting NF-κB has been proposed as anapproach to the treatment
of acute and chronic inﬂammatory conditions, and the use of inhibitors speciﬁc for either IKKβ or IKKγ has now been found to
inhibit neurodegeneration of TH+ DA-producing neurons in murine and primate models of Parkinson’s disease. These studies
suggest that targeting the classical pathway of NF-κB through the inhibition of the IKK complex can serve as a useful therapeutic
approach to the treatment of PD.
1.Introduction
Parkinson’s disease (PD) is a progressive degenerative dis-
order of the central nervous system (CNS) that leads to
impairment of motor skills and speech, as well as other
functions. While the disease mechanisms that ultimately
cause PD are still unclear, it is believed that the progressive
nature of PD is characterized by chronic inﬂammation-
induced neurodegeneration of dopamine-producing neu-
rons within the substantia nigra (SN) and striatum [1–4].
It is now well documented that microglial activation results
in the loss of dopaminergic neurons (DA-neurons). The
premise of microglia activation in PD has been supported
by analysis of postmortem brains from PD patients, which
provides clear evidence of microglia activation in the SN.
In the brains of patients with PD, large numbers of human
leukocyte antigen (HLA-DR) and CD11b-positive reactive
microglia were found in the SN, a region in which the
degeneration of DA-neurons was most prominent [5–8].
In addition, levels of proinﬂammatory mediators, including
TNFα,I L - 1 β, IL-6, and eicosanoids are elevated in the
brains and peripheral blood mononuclear cells (PBMCs) of
patients with PD [6, 7]. Nitrite in the cerebrospinal ﬂuid
as well as increased expression of inducible nitric oxide
synthase (iNOS) within the SN have been found in PD
patients [9, 10]. All of these ﬁndings lend strong support
to the association of inﬂammation and PD. Many of these
inﬂammatory mediators have been demonstrated to have
strong neurotoxic eﬀects on DA-neurons [1, 11–14], and
the central cell implicated in the initiation and execution
of inﬂammatory responses within the CNS is the microglial
cell. The pro-inﬂammatory response of the microglial cell
is primarily mediated by the transcription factor NF-κB,
which is activated by pro-inﬂammatory signals and controls2 Parkinson’s Disease
the gene expression of most of the inﬂammatory mediators
produced by microglial cells. Understanding the role of
inﬂammation in the etiology of PD, developing eﬀective
anti-inﬂammatory therapies directed at NF-κBa c t i v i t yi n
microglia, and determining the eﬃcacy of these NF-κB
inhibitors in protecting DA-neurons from degeneration are
of particular interest as therapeutic approaches aimed at
stopping and reversing the debilitating eﬀects of PD.
2.Microglial Cells,PD, and
Mechanisms of Inﬂammation
The etiology of PD suggests that chronic production of
inﬂammatory mediators such as TNFα,n i t r i co x i d e( N O ) ,
and IL-1β mediates a signiﬁcant amount of neuronal tissue
destruction,and themajor cellwithin theCNS thatproduces
these mediators is the microglial cell. Several agents which
directly activate microglia have been shown to induce
neurotoxicity to DA-producing neurons both in vitro and
in vivo. These include LPS [14], f-Met-Leu-Phe (fMLP),
β-amyloid peptides [15], Parkin [16], and aggregated or
nitrated-α-synuclein [17]. In addition, several direct neuro-
toxinssuch as1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) and 6-hydroxydopamine (6-OHDA) can activate
microglia through the release of cellular contents, which
leads to an exacerbation of the neurotoxicity [18–21]. There
is also a strong correlation between environmental factors
which lead to the induction of an inﬂammatory response
within the brain, including traumatic brain injury [22, 23]
and infection [24], and the ultimate onset of PD. Once
activated, microglial cells produce a wide variety of inﬂam-
matory mediators which servetopromotean innate immune
response, including inﬂammatory cytokines, chemokines,
prostaglandins and leukotrienes, NO, reactive oxygenspecies
(ROS), and glutamate.
Figure 1 proposesourmodel onthe roleofinﬂammation
in progressive neurodegeneration like that seen in PD.
Pro-inﬂammatory signals such as infection, trauma, stress,
or exposure to environmental factors can directly activate
microglial cells. Activated microglial cells, like macrophages,
undergo changes that enhance their microbicidal eﬀective-
ness and their ability to modulate the inﬂammatory immune
response.Thesechangesincludeenhancedphagocyticability,
microbial killing, antigen presentation, and inﬂammatory
cytokine production. Activated microglial cells then secrete
these inﬂammatory cytokines, such as TNF-α,I L - 1 β,M I P -
1α,a n dI L - 6[ 25], which can both recruit new inﬂammatory
cells as well as lead to direct killing of DA neurons.
Activated microglial cells also release NO, which is
produced by inducible nitric oxide synthase (iNOS) [26].
Furthermore, microglial cell activation leads to enhanced
respiratory burst activity as well. The microglial respiratory
burst is characterized by the release of various reactive oxy-
gen species (ROS) including superoxide radicals and hydro-
gen peroxide. It is now clear that many of the inﬂammatory
mediators produced by activated microglia can actively
trigger apoptosis in neuronal cell cultures. These mediators
include tumor necrosis factor-α (TNF-α)[ 27]n i t r i co x i d e
(NO),interleukin-1β (IL-1b, cathepsin-B) [7, 28], glutamate
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[29, 30], IL-8 [31], and ROS [10]. Highly elevated levels of
several of these inﬂammatory mediators (TNF, NO, PGE2,
IL-1β, IL-6) can be found in the cerebrospinal ﬂuid (CSF) of
PDpatients, aswell asinthebrainSNpctissueofPDpatients
when analyzed in postmortem autopsies[7,9,10,27,32, 33].
Interestingly, NF-κB activation is required for all of these
mediators to be produced by microglial cells. In addition,
microglial cells can be activated following the death of DA-
neuronsfromeitherinﬂammatory damageorfromthedirect
eﬀects of DA-neurotoxins such as MPTP or 6-OHDA. It has
also been found that intranigral and/or plasma TNF levels
remained elevated in MPTP-treated rodents or nonhuman
primates one year after administration of the neurotoxin
[34]. Once microglial cells have been activated to release
neurotoxic inﬂammatory mediators, further DA neuronal
damage occurs which results in the generation of reactive
microgliosis, a process by which there is a self-perpetuating
cycle resulting in sustained chronic neuroinﬂammation that
drivesthe progressive neurodegenerationinPD.This process
leads to the chronic nature of the disease and to sustained
neuronaldamageoveraprolongedperiodoftime.Therefore,
intervention with anti-inﬂammatory reagents such as NF-κB
inhibitors could function to inhibit the initial activation of
microglial cells or to halt the continual reactivation which
occurs during reactive microgliosis, which is the hallmark
of this chronic inﬂammatory condition. Ultimately, reactive
microgliosis, if left unchecked, will result in destruction of
DA-producing neurons.
3.The Biology ofNF-κB
Many of the inﬂammatory mediators involved in inﬂam-
mation and DA neurodegeneration in PD have a common
feature: their expression in microglial cells is primarily
regulated by NF-κB. The transcription factor NF-κB, ﬁrst
described by David Baltimore’s group in 1986 as a tran-
scription factor which is essential for the expression of
mouse kappa light chain genes [35, 36], has now been found
to control gene expression of many of proinﬂammatory
responses. NF-κB is a “master switch” for inﬂammatoryParkinson’s Disease 3
gene expression [37]. Inﬂammatory cytokines such as TNF
and IL-1α and β, bacterial products such as lipopolysac-
charide (LPS), and products of cellular damage strongly
activate inﬂammatory responses through the activation
of NF-κB. NFκB subsequently plays an essential role in
the inﬂammatory response through regulation of genes
encoding inﬂammatory cytokines (IL-1β,T N F α, IL-12/23),
chemokines (IL-8, MIP-1α,M C P - 1[ 38–40]), nitric oxide
production (iNOS), NADPH oxidase subunits p47 and p67
[41, 42], and adhesion molecules (ICAM-1, VCAM, and
E-selectin [43, 44]). Activation of NF-κBi sak e ye v e n t
in many chronic inﬂammatory diseases such as asthma,
cardiovascular disease [45], tissue reperfusion injury [46],
experimental autoimmune encephalomyelitis (EAE) [47],
rheumatoid arthritis [48], and inﬂammatory bowel disease
(IBD) [49]. Many of the standard agents used to treat
human inﬂammatory conditions, including sulfasalazine, 5-
aminosalicylates, and corticosteroids, as well as some natural
anti-inﬂammatory compounds such as IL-10, TGFβ1, β2AR
agonists, glutamate, and curcumin, among others, have
been postulated to exert some of their anti-inﬂammatory
eﬀects through NF-κB inhibition [41, 50–52]. We and others
have found that these compounds are potent inhibitors of
microglial activation and are neuroprotective to DA neurons
in vitro and/or in vivo.T h u s ,N F - κBa c t i v i t ye m e r g e sa sa
key target to control the chronic inﬂammation in humans,
and strategies for its use in PD to inhibit NF-κBa c t i v i t y
in microglial cells more potently may lead to more eﬀective
treatments for PD.
The NF-κB family consists of dimeric transcription
factors which include ﬁve members: c-Rel, RelA (p65), RelB,
NF-κB1 (p50/p105), and NF-κB2 (p52/p100). There are
two major pathways of activation: the classical or canonical
pathway and the alternate or noncanonical pathway. The
classical pathway, which is thought to regulate the pro-
duction of most pro-inﬂammatory mediators, is mediated
through the activation of a dimer of Rel proteins p50 and
p65, complexed within the cytosol to the inhibitory complex
IκBα [41]. The activation of the classical NF-κBp a t h w a y
is dependent on the phosphorylation, ubiquitination, and
subsequentproteasome-dependentdegradationofIκBα.The
phosphorylation of IκBα on serine residues is mediated by
IκB kinase (IKK), which is a molecular complex of three
proteins consisting of a heterodimer of the two catalytic
units IKKα and IKKβ, along with IKKγ (the NF-κB essential
modulator, NEMO) [53–55]. Mice null for IKKβ,I K K γ,
or p65 but not IKKα are embryonic lethal as a result of
massive liver apoptosis. Cells derived from these embryos
are unresponsive to classical NF-κB inducers such as TNFα
and IL-1β [56–58], demonstrating a signaling link between
p65, IKKβ,a n dI K K γ subunits. Activation of the IKK in
response to inﬂammatory mediators like TNFα,I L - 1 β,a n d
LPS depends critically on the presence of the IKKγ (NEMO)
subunit of the IKK complex [55, 59]a n dr e s u l t si nt h e
phosphorylation of the IκBb yt h ek i n a s ea c t i v i t yo fI K K β
[53, 54]. An N-terminal region of NEMO associates with a
hexapeptide sequence within the C-terminus of both IKKα
and IKKβ, named the NEMO-binding domain (NBD), and
disruption or mutation of this NEMO-NBD interaction site
on either IKKβ or IKKγ results in a loss of responsiveness of
cells to pro-inﬂammatory signaling.
On the other hand, the noncanonical pathway of NF-κB
consists of heterodimers of Rel proteins p100/RelB that also
have transcriptional activity but appear to play more of
a regulatory role in cellular activation and diﬀerentiation
rather than in inﬂammation. In response to a set of
factors that include CD40L, B cell-activating factor, and
lymphotoxin-β,N F - κB is activated through an alternative
pathway independent of IKK [60–65]. Instead, activation
proceeds through the NF-κB-inducing kinase (NIK) that
phosphorylates and activates IKKαα homodimers which,
in turn, phosphorylate p100 in complex with RelB. This
leads to ubiquitin-dependent processing of p100 to p52 and
translocation of p52/RelB to the nucleus [63, 64]. Cytokine-
induced activation of the noncanonical pathway of NF-κBi s
accompanied by an increase in the concentration of nuclear
IKKα that phosphorylates histone H3 [66, 67]. In cells
exposedtocytokines,nuclearIKKαregulates gene expression
through promoter-associated histone phosphorylation and
binding to promoter regions of NF-κB responsive genes.
Mice deﬁcient in IKKα die perinatally, with phenotypical
changes of dermal and skeletal development [68–71]. B-cell
activating factor, NIK, and p100/p52 knockout mice have
similar phenotypes [72, 73], suggesting that these molecules
are all part of the same linear nonclassical signaling cascade.
In addition, the classical and alternative pathways are
thoughttoregulate distinctgenesin response totheirvarious
activators [65]. Relevant to PD, it has now been found that
the canonical pathway is highly activated within the SN
of animals undergoing DA neurodegeneration, and after-
mortem in the brains of PD patients [74, 75]. On the
other hand, the non-canonical NF-κBp a t h w a yi sf o u n dt o
be activated in regenerating DA-neurons from rats treated
with glial-derived neurotrophic factor (GDNF), while the
canonical p65/p50 pathway is concomitantly decreased, sug-
gesting that this non-canonical NF-κB pathway is important
in neuron regeneration of DA neurons within the SN [76].
4.TherapeuticUsage ofSpeciﬁcNF-κB
Inhibitors inChronic Inﬂammation
Due to the central role of the IKKγ and Ikkβ molecules
within the IKK complex in activating inﬂammation, the
identiﬁcation of selective IKKβ and IKKγ inhibitors that do
not target IKKα or the P100/p52 pathway as therapeutic
agents in treating chronic inﬂammation is of considerable
interest. Two speciﬁc inhibitors of NF-κBh a v ee m e r g e dt h a t
appear to be highly therapeutically active in the treatment
of several chronic inﬂammatory diseases, and which provide
possible therapeutic approaches to the treatment of PD. The
ﬁrst is a peptide directed against the N-terminal region of
NEMO that associates with a hexapeptide sequence within
the C-terminus of both IKKα and IKKβ,n a m e dt h eN E M O -
binding domain (NBD). This cell permeable peptide spans
the NBDand disrupts theassociation of NEMOwith IKKsin
vitroand blocksTNFα-induced NF-κBacti vationin vivo [77,
78]. Notably, the NBD peptide does not aﬀect basal activity
of the IKK but only suppresses the induction of activity4 Parkinson’s Disease
in response to inﬂammatory cytokines [77]. Continuous
administration of the NBD peptide eﬀectively ameliorates
inﬂammatory responses in animal models without overt
signs of toxicity [78]. Additionally, in mouse models of
chronic inﬂammation, including collagen-induced arthritis
(CIA) [79, 80], experimental allergic encephalomyelitis
(EAE), Duchenne’s muscular dystrophy (Peterson et al.,
manuscript in submission), and inﬂammatory bowel disease
(IBD) [81], in vivo treatment with NBD peptides blocked
disease activity, inﬂammatory cytokine expression, and
homing of cells to inﬂammatory sites. Furthermore, mice
treated systemically with an NBD peptide for ﬁve days
after induction of CIA maintained clinical and histological
improvement for nearly three weeks following termination
of peptide administration [79]. It is important to note
that in the therapeutic use of NBD peptide, there was no
evidence of undesired oﬀ-target eﬀects as the treatment with
NBD peptide was shown to be speciﬁc for inhibiting NF-
κB signaling, exhibiting no inhibitory eﬀects towards JNK
or p38 MAPK pathways [78]. The safety proﬁle for NBD is
favorable as well. In vivo, systemic delivery of NBD is not
associated with any described toxicity in mice or rats, and
inhibition of NF-κB has been demonstrated to ameliorate
an ever-growing list ofinﬂammatory disease conditions [77–
79,82,83].Therefore,thetherapeuticeﬀectoftheshort-lived
NBD peptide may far outlast its pharmacokinetic properties.
Thus,selectiveIKKinhibitionbyNBDpeptidesmay(i)bean
eﬀective therapeutic intervention in chronic inﬂammatory
diseases; (ii) lead to durable alterations in immune responses
that correlate with durable clinical eﬃcacy; (iii) minimize
potential toxicity concerns associated as basal NF-κBa c t i v i t y
remains intact as does the alternative pathway of NF-κB
activation necessary for B-cell development and lymphoid
organogenesis.
A second approach to the inhibition of inﬂammation
has been to utilize small molecule inhibitors that speciﬁcally
block the kinase enzymatic activity of IKKβ.O n es u c h
speciﬁc inhibitor, called Compound A, is a small molecule
inhibitor of the kinase activity of IKKβ but not IKKα.
Compound A, also known as BAY-65-1942 (7-[2-(cyclo-
propylmethoxy)-6-hydroxyphenyl]-5-[(3S)-3-piperidinyl]-
1,4-dihydro-2Hpyrido [2,3-d] [1,3]-oxazin-2-one hydro-
chloride), has been shown to speciﬁcally and eﬀectively
block the catalytic activity of IKKβ, inhibiting its ability
to phosphorylate IκB and activate the cytosolic p50/p65
NF-κB heterodimers [84, 85]. Compound A has been used
extensively in vivo, and it has now been found to prevent
pulmonary inﬂammation [86], to attenuate myocardial
injury and dysfunction after ischemia-reperfusion injury
[84], and to prevent graft versus host disease in murine
models of GVHD (Serody et al., personal communication).
Other IKKβ inhibitors, including PS-1145 [87]a n dT P C A - 1
[88], have been shown to eﬀectively prevent graft versus
host disease in a murine bone marrow transplant model
[89], to enhance sensitivity of multiple myeloma cells to
chemotherapy by inhibiting the protective eﬀects of NF-κB
[90], to inhibit melanoma growth in vivo [91–93], and to
inhibit the growth of colon cancer [94]. These inhibitors
work primarily through the inhibition of IKKβ,a n dt h e i r
speciﬁc suppression of the canonical NF-κB signaling
pathway and consequent decrease in serum levels of TNFα
andIL-6arethemainfeatureswhich mediatetheirinhibitory
activity.
5.NF-κBand DA Neuroinﬂammation
We have found that a number of anti-inﬂammatory
compounds have been demonstrated to have eﬃcacy in
protecting DA-neurons from degeneration mediated by
inﬂammatory damage. These compounds include IL-10
[95, 96], TGFβ1[ 97, 98], morphinan derivatives [99], and
DPI, an inhibitor of oxidative stress responses [100]. It is
well known that while these compounds have numerous
regulatory eﬀects on multiple biological targets, one of their
primary anti-inﬂammatory features is the inhibition of NF-
κB within macrophages and microglial cells [101]. Recently,
it has been demonstrated that several other compounds,
including pioglitazone (a PPARγ agonist), curcumin [102],
and salmeterol (a β2AR agonist, our reference [103]), func-
tion to inhibit DA neurodegeneration by inhibiting NF-κB.
However, the most compelling data suggesting a central role
for NF-κBa sar e g u l a t o r yt a r g e tf o rP Dt h e r a p yc o m e sf r o m
theuseofspeciﬁc NF-κBinhibitors,which haverecentlybeen
used in murine models of PD to determine if therapeutic
administration of these inhibitors could halt the progression
of neurodegeneration induced by the neurotoxin MPTP
[104] or by activation of CNS inﬂammation by the intracra-
nial injection of LPS [105]. Compounds that block the
activation of NF-κB are capable of inhibiting the two major
inﬂammatory pathwaysinmicroglia—activationofoxidative
stress and production of inﬂammatory mediators, including
cytokines TNFα,I L - 1 β,a n dI L - 6 ,a sw e l la sc h e m o k i n e s
associated with inﬂammation [101]. Ghosh et al. have used
the NBD peptide and a mutant peptide control to study
the eﬃcacy of NF-κB inhibition in stopping or reversing
the neurodegenerative eﬀects of MPTP administration in a
murine model of PD [104]. Evidence shows that there is a
marked increase in NF-κB activation within the midbrain
of animals undergoing neurodegeneration as a result of
M P T Pa d m i n i s t r a t i o n ,a sw e l la si nt h eS N p co fP Dp a t i e n t s
[75, 104], and this activation occurs in the TH+ DA-neurons
and in astrocytes and microglia. Administration of NBD
peptide but not the mutant control peptide was shown to
inhibitMPP+inducedNF-κBactivationinvitroinmicroglia,
astrocytes, as well as in BV-2 microglial cells, as determined
by DNA binding and transcriptional activity. More impor-
tantly, administration of NBD peptide but not the mutant
peptide prior to the injection of MPTP in vivo signiﬁcantly
inhibits the activation of NF-κB within the midbrain region.
This inhibition of NF-κB activation is accompanied by a
concomitant reduction in inﬂammatory mediator mRNA
expression within the SNpc, as well as the expression of
activation markers CD11b and GFAP by microglia and
astrocytes, respectively. Mice receiving NBD peptide but not
mutant peptide prior to MPTP injection also showed highly
signiﬁcant protection of the nigrostriatum from MPTP-
induced neurodegeneration of the TH+ neurons and the loss
of dopamine production, as well as improvement in theirParkinson’s Disease 5
locomotor function compared with MPTP-injected mice
given mutant peptide. More importantly, administration of
NBD peptide 2 days subsequent to the injection of MPTP
shows substantial protection of TH+ neurons, suggesting
that NBD peptide can be used therapeutically to slow down
or halt the progression of DA neurodegeneration in MPTP-
treatedanimals[104].Infrared analysisofthebrainsofNBD-
treated animals determined that peptide could be found
within the brain tissue in signiﬁcant quantities, suggesting
that the NBD peptide could cross the blood-brain barrier
(BBB) and reach the site of inﬂammation. It remains to be
determined the mechanism of NF-κB inhibition within the
SNpc, but these data suggest that NF-κBi sav i a b l et a r g e tf o r
therapy for PD patients.
Subsequently, we have used the IKKβ inhibitor com-
pound A in LPS-induced neurodegenerationto determine if,
similar to NBD peptide, inhibition of the canonical NF-κB
pathway could halt inﬂammation-induced DA neurodegen-
eration. In this model, LPS is injected directly into one side
of the midbrain of rats, leading to inﬂammation-induced
degeneration of DA-neurons [105]. It was found that IKKβ
inhibitor compound A was capable of strongly inhibiting the
activation of NF-κB in vitro and in vivo,a sw e l la st h em R N A
expression and subsequent release of pro-inﬂammatory
mediators. Compound A also signiﬁcantly inhibited LPS-
and MPTP-induced DA neurotoxicity in vitro,a n dt h i s
neuroprotective activity required the presence of microglial
cells. Most importantly, administration of compound A
to animals injected intranigrally with LPS attenuated LPS
injection-induced DA neuronal loss and microglia activation
within the SNpc [105]. Taken together, these data provide
strong evidence that NF-κBo ﬀers an excellent therapeutic
target to inhibit DA neurodegeneration, and that signiﬁcant
additional work needs to be performed to determine the
optimal approach and agent best suited for the treatment of
PD.
6.Conclusion
Strong evidence now exists that inﬂammation plays a key
role in the neurodegeneration seen in PD, and that eﬀective
anti-inﬂammatory therapy can be very useful in slowing
down or preventing the chronic destruction of DA-neurons
which is the hallmark of the disease. While a number
of anti-inﬂammatories have already been developed and
utilized, many of these compounds have multiple oﬀ-target
eﬀects or do not show strong eﬃcacy in the treatment
of PD. In addition, it is not yet clear the best target
for anti-inﬂammatory therapy in PD and other chronic
inﬂammatory conditions. NF-κB, the “master switch” of
inﬂammation, oﬀers an ideal target for therapy because of
its key role in the production of the inﬂammatory mediators
known to exhibit DA neurotoxicity in vitro and in vivo.
Targeting the activation pathway of NF-κB by inhibiting the
IKK complex has now been shown to be a highly eﬀective
therapy for the treatment of neurodegeneration in murine
models of PD and oﬀers us a new avenue of investigation
towards the development of more eﬀective therapies aimed
at stopping and reversing DA-neuron loss in this disease.
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